ARCHIVES

ODAC Votes 13:0 For Approving Perjeta

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

White House Announces FDA Initiatives To accelerate Cancer Drug Approval

April 4, 1996

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

July 30, 2004

Drug Combination Tested For B.C. Brain Metastases

January 25, 2008

In Brief: HHS Drags Feet, NCI Considering Contract To Review Cancer Research Facility Needs

October 14, 1983

In Brief: Satcher Confirmed For U.S. Surgeon General; Bishop Selected As Chancellor Of UCSF

February 13, 1998